top of page
Tixupharma
Autocrine signalling in pursue of tissue renovation
Regulatory & Strategic Flexibility
The pharmaceutical proposition is grounded on regulatory package of TP7193 and its derivatives. A fast-track clinical operations and/or market entries by a flexible regulatory approach. Beside licensing/distribution deals, the initiative is also open to codev agreement by single asset, or long-terms collaboration on R&D.
bottom of page